Navigation Links
ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
Date:4/28/2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended March 31, 2011.  Revenue for the quarter ended March 31, 2011 was $313.3 million, a 12% increase (also a 12% increase on a constant currency basis) over the quarter ended March 31, 2010.  For the quarter ended March 31, 2011, income from operations was $64.0 million and net income was $53.4 million, an increase of 5% and 9%, respectively, compared to the quarter ended March 31, 2010.  Diluted earnings per share for the quarter ended March 31, 2011 were $0.34, an increase of 10% compared to the quarter ended March 31, 2010.  

(Logo:  http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

SG&A expenses were $92.5 million for the quarter ended March 31, 2011, an increase of $8.4 million, or 10% (an 8% increase on a constant currency basis) compared to the quarter ended March 31, 2010.  SG&A costs were 29.5% of revenue in the quarter ended March 31, 2011, compared to 30.2% for the quarter ended March 31, 2010.R&D expenses were $23.3 million for the quarter ended March 31, 2011, or 7.4% of revenue.  R&D expenses increased by 28% (an 18% increase on a constant currency basis) compared to the quarter ended March 31, 2010.  R&D expenses were negatively impacted by the appreciation of the Australian dollar against the U.S. dollar.

The company amortized acquired intangibles of $2.7 million ($1.8 million, net of tax) during the quarter ended March 31, 2011.  Stock-based compensation costs incurred during the quarter ended March 31, 2011 of $6.8 million ($4.8 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.  

For the nine months ended March 31, 2011, revenue was $901.3 million, an increase of 13% over the nine months ended March 31, 2010 (a 14% increase on a constant currency basis).  For the nine months ended March 31, 2011, income from operations and net income were $200.2 million and $168.5 million, an increase of 17% and 23%, respectively, compared to the nine months ended March 31, 2010.  Diluted earnings per share for the nine months ended March 31, 2011 were $1.07 per diluted share, an increase of 20% compared to the nine months ended March 31, 2010.

Inventory, at $205.0 million, increased by $19.4 million compared to June 30, 2010.  Accounts receivable days sales outstanding, at 68 days, decreased by 3 days compared to June 30, 2010.  

Peter C. Farrell PhD, Chairman and Chief Executive Officer, commented, "In the third quarter of fiscal 2011 we continued to show strong year-over-year growth especially in Europe and the Asia-Pacific region.  Revenue outside the Americas increased by 16% to $152.7 million over the prior year's quarter, or a 15% increase on a constant currency basis.
Revenue in the Americas increased by over 9% to $160.5 million over the prior year's quarter. Americas' revenues continued to be adversely impacted by reduced bilevel sales, but we expect that the recent launch of the S9™ bilevel series will help to reverse this trend. Worldwide, our growth in flow generators was mainly driven by sales of the S9 AutoSet™.  Patient interface sales did extremely well in all regions. With the recent launches of the Quattro™ FX full face mask and the Mirage™ FX nasal mask, we have completed the release of the trilogy of masks in the FX series.  Operating profit for the March quarter was $64.0 million and cash flow from operations was a record $81.4 million, demonstrating excellent operating performance.

"We expect the growth of all our products to continue to benefit from the vastly under-penetrated and growing sleep-disordered breathing market.  Due to the strong correlation between sleep-disordered breathing and comorbidities, such as heart disease and diabetes, chronic obstructive pulmonary disease, perioperative death and occupational health and safety, we believe that there are significant opportunities to further penetrate the market. In addition, findings from clinical studies continue to demonstrate the importance of diagnosing and treating sleep-disordered breathing.  Increasingly, there is evidence coming to light that early intervention in the treatment of sleep-disordered breathing may slow or prevent the progression of chronic diseases."

About ResMedResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. US Pacific Time today to discuss these quarterly results.  Individuals wishing to access the conference call may do so via ResMed's Website at www.resmed.com or by dialing 617-614-4910 (domestic) or +1 617-614-4910 (international) and entering conference pass code no. 57596192. Please allow extra time prior to the call to visit the Website and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast.  The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks.  A telephone replay of the conference call is available by dialing 617-801-6888 (domestic) and +1 617-801-6888 (international) and entering conference I.D. No. 68716093.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Website at www.resmed.com.  

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Website.RESMED INC AND SUBSIDIARIESCondensed Consolidated Statements of Income (Unaudited)

(In US$ thousands, except per share data)Three Months Ended

March 31,

Nine Months Ended

March 31,2011

2010

2011

2010Net revenue

$313,258

$278,659

$901,255

$800,785Cost of sales

130,755

112,076

358,800

319,819Gross profit

182,503

166,583

542,455

480,966Operating expenses:Selling, general and administrative

92,549

84,133

268,920

244,984Research and development

23,319

18,279

65,032

55,252Amortization of acquired intangible assets

2,673

1,992

7,276

5,967Donation to Foundation

-

1,000

1,000

3,000Total operating expenses

118,541

105,404

342,228

309,203Income from operations

63,962

61,179

200,227

171,763Other income (expenses), net:Interest income (expense), net

6,663

4,092

17,765

9,383Other, net

398

2,387

8,506

7,515Total other income (expenses), net

7,061

6,479

26,271

16,898Income before income taxes

71,023

67,658

226,498

188,661Income taxes

17,673

18,824

57,984

51,742Net income

$53,350

$48,834

$168,514

$136,919Basic earnings per share

$0.35

$0.32

$1.11

$0.91Diluted earnings per share

$0.34

$0.31

$1.07

$0.89Basic shares outstanding

153,251

150,876

152,407

150,648Diluted shares outstanding

157,616

155,660

157,356

154,528All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 5, 2010 and distributed on August 30, 2010.

RESMED INC AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited)

(In US$ thousands except share and per share data)March 31,

June 30,2011

2010ASSETSCurrent assets:Cash and cash equivalents

$671,704

$488,776Accounts receivable, net

251,935

226,911Inventories

205,000

185,642Deferred income taxes

12,220

14,112Income taxes receivable

7,306

5,317Prepaid expenses and other current assets

54,493

64,583Total current assets

1,202,658

985,341Property, plant and equipment, net

447,669

387,148Goodwill

230,855

198,625Other intangibles

49,236

30,925Deferred income taxes

19,999

19,042Other assets

11,742

5,316Total non-current assets

759,501

641,056Total assets

$1,962,159

$1,626,397LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

52,370

57,535Accrued expenses

90,353

80,883Deferred revenue

42,133

29,507Income taxes payable

5,783

22,656Deferred income taxes

497

402Current portion of long-term debt

235

121,689Total current liabilities

191,371

312,672Non-current liabilities:Deferred income taxes

9,376

10,793Deferred revenue

16,588

12,755Income taxes payable

1,434

2,641Non Current portion of long-term debt

80,000

0Total non-current liabilities

107,398

26,189Total liabilities

298,769

338,861STOCKHOLDERS' EQUITY:Common stock

614

605Additional paid-in capital

767,436

660,185Retained earnings

1,053,390

884,876Treasury stock

(440,635)

(344,505)Accumulated other comprehensive income

282,585

86,375Total stockholders' equity

1,663,390

1,287,536Total liabilities and stockholders' equity

$1,962,159

$1,626,397
'/>"/>

SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
3. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
4. ResMed Inc. to Present at Upcoming Conferences
5. ResMed Announces Deferred Conversions in Connection With Stock Split
6. ResMed Inc. Announces Completion of Two-for-One Stock Split
7. Study Shows ResMeds New CPAP Device Increases Patient Compliance
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results
9. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010
10. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
11. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Six Months Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 --> ... Inflammation Global Clinical Trials Review, H2, 2015 provides ... clinical trials landscape along with top level data ... (G7 & E7), Trial Status, Trial Phase, Sponsor ... companies involved and enlists all trials (Trial title, ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... an upcoming Feb. 24 webinar that will discuss ways health plans and PBMs ... as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat ...
(Date:2/12/2016)... OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism Spectrum ... this dance is to provide a night of fun for teens with and without special ... everyone feel welcomed and included at the event. The dance will take place on Saturday, ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative dentistry, ... of dental decay. With the recent approval by the FDA, there is a now ... similar to fluoride varnish, SDF is very simple and quick to apply. The application ...
(Date:2/11/2016)... ... 2016 , ... SPH Analytics announced today that DeKalb ... solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership brings ... contract were not disclosed. , As the healthcare market moves towards quality-based outcomes, ...
(Date:2/11/2016)... ... ... The Journal of Pain Research has seen a significant increase ... taken from the Scopus database (Elsevier B.V.) and is a measure of a journal's ... over a three year period and also the importance of the journals where the ...
Breaking Medicine News(10 mins):